ADVERTISEMENT

Dolat Capital: Laurus Labs’ Strong Beat In Q2, Guidance Maintained  

Dolat Capital: Laurus Labs’ Strong Beat In Q2, Guidance Maintained

The antiviral medication being manufactured in Russia. (Photographer Andrey Rudakov/Bloomberg)
The antiviral medication being manufactured in Russia. (Photographer Andrey Rudakov/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Laurus Labs Ltd. reported robust Q2 beating our estimates primarily driven by stellar growth in formulations.

Though majority growth is led by anti-retroviral tender based opportunities, leveraging its backward integration, the company has demonstrated commendable execution capability as the growth is volume led without any one-offs.

Management remained confident of growth sustenance in H2 as well.

Click on the attachment to read the full report:

Dolat Capital Laurus Labs Q2FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.